Vyome Holdings (HIND)

Its pipeline includes VT-1953, a topical gel being developed for the signs and symptoms of malignant fungating wounds in cancer patients. These wounds can be difficult to manage and may involve pain, infection risk, odor, and quality-of-life challenges. Vyome is also developing VT-1908, a repurposed immune modulator being evaluated as a steroid-sparing treatment for anterior uveitis, an inflammatory eye condition. Another candidate, VB1953, is being advanced for moderate to severe acne.

In addition to its drug development work, Vyome has commercialized reformulated topical antifungal products in India using its Molecular Replacement Therapeutics platform. These include a dandruff lotion and shampoo, giving the company a commercial footprint alongside its biotechnology research activities. Vyome reports operations across pharmaceutical products and biotechnology, with pharmaceutical products currently contributing the larger share of revenue.

As a listed clinical-stage biopharmaceutical company, Vyome’s prospects depend heavily on the progress of its development programs, regulatory outcomes, clinical data, commercialization strategy, and access to capital. Its distinguishing feature is the combination of dermatology and immune-inflammatory expertise with a pipeline that targets conditions ranging from cancer-related wound care to ocular inflammation and acne.